June 2, 2016 8:27 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Echo Therapeutics, Inc. (NASDAQ: ECTE) revealed that it was in the final stage of selecting a Clinical Research Organization (CRO) for the development of a comprehensive regulatory, as well as, clinical strategy for its CGM system. Echo Therapeutics said that following its ongoing diligence process, it would select a full-service CRO with a global reach and a demonstrated track record of successfully designing and managing clinical trials.The company's President and CEO, Scott Hollander, commented, "Identifying the right CRO partner is critical to our success. We are currently in discussions to determine the organization best suited to develop and execute our strategy and to provide consultation as we progress with product development. Based on our progress, I am excited to begin plans for the future clinical trial of our NextGen system."On Wednesday, the stock traded 3.57 percent higher.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.